Olax Pharma Labs Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 13 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth -19.75%
- Profit Growth -56.41%
- Ebitda -54.21%
- Net Worth 14.04%
- Total Assets 39.99%
About Olax Pharma Labs
Olax Pharma Labs Private Limited (OPLPL) is a Private Limited Indian Non-Government Company incorporated in India on 05 April 2011 and has a history of 13 years and ten months. Its registered office is in Siddipet, Telangana, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Sandeep Yadav and Suman Kumari serve as directors at the Company.
Company Details
-
Location
Siddipet, Telangana, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24232TG2011PTC073694
-
Company No.
073694
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
05 Apr 2011
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Hyderabad
Industry
What products or services does Olax Pharma Labs Private Limited offer?
Olax Pharma Labs Private Limited offers a wide range of products and services, including Water Testing Services, Ground Water Chemical Analysis, API Intermediate, API Impurities, Anti Corrosion Products, Acetylacetone, Blood System and Cardiovascular API, Halogenating Agent, 1-Bromo-3-chloropropane, Pharma Ingredients & Raw Materials.
Who are the key members and board of directors at Olax Pharma Labs?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sandeep Yadav
|
Director | 13-Nov-2013 | Current |
|
Suman Kumari
|
Director | 05-Apr-2011 | Current |
Financial Performance of Olax Pharma Labs.
Olax Pharma Labs Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 19.75% decrease. The company also saw a substantial fall in profitability, with a 56.41% decrease in profit. The company's net worth Soared by an impressive increase of 14.04%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Olax Pharma Labs?
In 2023, Olax Pharma Labs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Olax Pharma Labs?
Unlock and access historical data on people associated with Olax Pharma Labs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Olax Pharma Labs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Olax Pharma Labs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
